e2d5a769_Fungal_Pneumonia__ication_for_Antifungal_Therapy
[Fungal Pathogen] Aspergillosis Rapid tapering of immunosuppressive agents and corticosteroids and reversal of neutropenia (if possible) [Antifungal Drugs Used] Voriconazole is the new standard of care for invasive aspergillosis based on superiority over amphotericin B in primary therapy Lipid formulations of amphotericin B have at least equal efficacy but less toxicity compared with amphotericin B desoxycholate Oral voriconazole can be used to complete treatment with initial response to IV voriconazole or amphotericin B Posaconazole is second line agent Echinocandins second line agent when voriconazole is not tolerated or in combination with voriconazole in an attempt to enhance antifungal activity
All patients with invasive disease; in patients who are immunosuppressed, early diagnosis and empiric treatment for persistent fever not responding to broad-spectrum antibiotics; high mortality once infiltrates and symptoms appear; prognosis ultimately linked to severity and outcome of underlying disease Mortality rate of 50-60% in patients with AIDS
Fungal Pneumonia
Indication for Antifungal Therapy